ZLAB vs. CERE, ITCI, LEGN, VKTX, BPMC, JAZZ, SMMT, IONS, OGN, and BBIO
Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Blueprint Medicines (BPMC), Jazz Pharmaceuticals (JAZZ), Summit Therapeutics (SMMT), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.
Zai Lab (NASDAQ:ZLAB) and Cerevel Therapeutics (NASDAQ:CERE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.
Zai Lab presently has a consensus target price of $64.22, indicating a potential upside of 232.94%. Cerevel Therapeutics has a consensus target price of $42.67, indicating a potential upside of 4.96%. Given Zai Lab's stronger consensus rating and higher possible upside, equities research analysts plainly believe Zai Lab is more favorable than Cerevel Therapeutics.
Cerevel Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -116.45%. Zai Lab's return on equity of -40.21% beat Cerevel Therapeutics' return on equity.
In the previous week, Cerevel Therapeutics had 4 more articles in the media than Zai Lab. MarketBeat recorded 10 mentions for Cerevel Therapeutics and 6 mentions for Zai Lab. Zai Lab's average media sentiment score of 1.16 beat Cerevel Therapeutics' score of 0.29 indicating that Zai Lab is being referred to more favorably in the media.
Zai Lab has higher revenue and earnings than Cerevel Therapeutics.
41.7% of Zai Lab shares are held by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are held by institutional investors. 5.2% of Zai Lab shares are held by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Zai Lab has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.
Zai Lab received 65 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 63.58% of users gave Zai Lab an outperform vote.
Summary
Zai Lab beats Cerevel Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Zai Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
